Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Sales (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Return on Sales data on record, last reported at 5.53% in Q3 2025.

  • For Q3 2025, Return on Sales rose 18030.0% year-over-year to 5.53%; the TTM value through Sep 2025 reached 5.53%, up 685.0%, while the annual FY2024 figure was 3.45%, 357.0% down from the prior year.
  • Return on Sales reached 5.53% in Q3 2025 per AMLX's latest filing, down from 7.07% in the prior quarter.
  • Across five years, Return on Sales topped out at 8.58% in Q1 2025 and bottomed at 538.25% in Q2 2022.
  • Average Return on Sales over 5 years is 98.7%, with a median of 1.34% recorded in 2024.
  • Peak YoY movement for Return on Sales: soared 53847bps in 2023, then plummeted -17500bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 308.53% in 2021, then surged by 99bps to 2.0% in 2022, then soared by 101bps to 0.02% in 2023, then soared by 5930bps to 1.38% in 2024, then surged by 302bps to 5.53% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 5.53% in Q3 2025, 7.07% in Q2 2025, and 8.58% in Q1 2025.